Affimed (AFMD) Reports Preclinical Data on Mechanism of Action of two Innate Cell Engagers, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. RH
3. NVDA
4. USO
5. SPCX
6. NDAQ
7. COGT
8. ELVN
9. ADAM
10. TIGCF

Go back to Affimed (AFMD) Reports Preclinical Data on Mechanism of Action of two Innate Cell Engagers, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

Affimed Therapeutics (AFMD) PT Lowered to $11 at Stifel

November 10, 2021 2:23 PM EST

Stifel analyst Bradley Canino lowered the price target on Affimed Therapeutics (NASDAQ: AFMD) to $11.00 (from $12.00) while maintaining a Buy rating.

The analyst commented, "AFMD's 3Q update included AFM24 dose-escalation data for the monotherapy 480mg recommended phase 2 dose (RP2D) where there were... More

Affimed (AFMD) Reports Q3 Loss of EUR0.14/sh

November 10, 2021 6:40 AM EST

Affimed (NASDAQ: AFMD) reported Q3 EPS of (EUR0.14), versus (EUR0.07) reported last year. Revenue for the quarter came in at EUR8.66 million, versus EUR10.55 million reported last year.

For earnings history and earnings-related data on Affimed (AFMD) click here.

... More